Phosphatidylserine Antibodies (IgM)
The Phosphatidylserine Antibodies (IgM) test is a specialised blood test used to detect the presence of IgM antibodies directed against phosphatidylserine, a phospholipid component of cell membranes. Phosphatidylserine plays an important role in cell structure and function, particularly in maintaining membrane integrity and participating in cell signalling and coagulation processes.
Under normal conditions, phosphatidylserine is located on the inner surface of the cell membrane. However, during cell damage, apoptosis (programmed cell death), or certain pathological states, it may become exposed on the outer surface. This exposure can trigger an immune response in some individuals, leading to the production of antiphospholipid antibodies, including phosphatidylserine antibodies.
The detection of IgM antibodies against phosphatidylserine is clinically relevant in the evaluation of autoimmune and thrombotic disorders. These antibodies are part of a broader group known as antiphospholipid antibodies, which are associated with an increased risk of abnormal blood clotting and certain pregnancy-related complications.
- Price: £80
- Code: PSM
- TAT: 10 Working Days
- Sample Type: Blood
Clinical Significance
Phosphatidylserine IgM antibodies are most commonly evaluated in the context of antiphospholipid syndrome (APS), an autoimmune condition characterised by an increased tendency for blood clot formation (thrombosis). APS may affect both veins and arteries and can lead to complications such as deep vein thrombosis, pulmonary embolism, or stroke.
The presence of antiphospholipid antibodies, including phosphatidylserine antibodies, may also be associated with recurrent pregnancy loss, pre-eclampsia, or other obstetric complications. Detecting these antibodies can therefore play an important role in assessing risk and guiding clinical management in individuals with a history of such events.
In addition to APS, elevated phosphatidylserine antibodies may be observed in certain autoimmune conditions, infections, or inflammatory states. However, their presence alone does not confirm a diagnosis and must be interpreted alongside other laboratory markers and clinical findings.
IgM antibodies often reflect more recent or active immune responses, whereas IgG antibodies may indicate longer-term or persistent immune activity. For this reason, clinicians may request both IgM and IgG antiphospholipid antibody tests to gain a more complete understanding of immune involvement.
Who Should Consider This Test?
The Phosphatidylserine IgM test may be recommended for individuals with a history of unexplained blood clots, particularly at a young age or in unusual locations. It is also commonly requested in patients with recurrent miscarriages or pregnancy complications where an autoimmune cause is suspected.
Individuals with known autoimmune conditions, such as systemic lupus erythematosus (SLE), may also undergo antiphospholipid antibody testing as part of a broader evaluation of disease activity and risk factors.
The test may also be considered for patients with unexplained prolonged clotting times or abnormal coagulation results, as well as those undergoing evaluation for suspected antiphospholipid syndrome.
Because these antibodies can sometimes appear transiently, repeat testing may be recommended in certain cases to confirm persistence and clinical relevance.
Sample Collection
This test requires a blood sample, which is collected by a trained healthcare professional using standard techniques. The procedure is quick and minimally invasive, typically completed within a few minutes.
Once collected, the sample is handled carefully and analysed using specialised immunological methods designed to detect phosphatidylserine-specific IgM antibodies. Proper sample handling and testing procedures ensure that results accurately reflect the immune status at the time of collection.
No special preparation is generally required before the test unless otherwise advised by a healthcare professional.
Understanding Your Results
Results from the Phosphatidylserine IgM test indicate whether these specific antibodies are present in the bloodstream. A positive result suggests the presence of antiphospholipid antibodies, which may be associated with an increased risk of thrombosis or autoimmune activity.
However, a single positive result does not necessarily confirm a diagnosis of antiphospholipid syndrome. Clinical diagnosis typically requires correlation with symptoms, medical history, and additional laboratory tests, including repeat antibody measurements over time.
A negative result indicates that phosphatidylserine IgM antibodies were not detected. This reduces the likelihood of antiphospholipid involvement but does not completely exclude other causes of clotting abnormalities or autoimmune disease.
Healthcare professionals interpret results within the broader clinical context to determine whether further investigation or management is required.
FAQs
When will I receive my results?
Results are usually available within the stated turnaround time.
Should I discuss my results with a doctor?
Yes, results should always be reviewed with a qualified healthcare professional.
Why Choose Marylebone Diagnostic Centre?
Marylebone Diagnostic Centre provides advanced immunology testing in a professional and patient-focused environment. Our approach ensures that each test is performed with attention to detail, supporting accurate assessment of autoimmune and clotting-related conditions.
With experienced healthcare staff and efficient turnaround times, we aim to make the testing process straightforward and reliable. Our services are designed to support clinicians and patients in gaining clear insights into complex immune-related conditions.
Book Now
Book the Phosphatidylserine Antibodies (IgM) (PSM) test today to support the evaluation of autoimmune activity and clotting risk.
